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PRM105
MeasuReMent equivalence and Patient PRefeRence foR the sf-36v2 on 
a handheld device and sMaRtPhone aPP
Khurana L.1, White M.K.2, Bjorner J.B.2, Gary S.T.1, Vazquez V.1, Otero A.1, Dallabrida S.1
1PHT Corporation, Boston, MA, USA, 2Optum PatientInsights, Lincoln, RI, USA
Objectives: The Short-Form 36 Health Survey version 2.0 (SF-36v2®) is a validated 
patient-reported outcome instrument. A validated single-item format version exists 
for deployment on computer screens/tablet-sized devices, and an electronic hand-
held version was developed in 2012. The objectives of this study were to evaluate 
measurement equivalence between the paper and electronic versions of the SF-36v2 
administered using a handheld device or a smartphone app, and to determine 
patient preference for mode of administration. MethOds: This was a randomized 
crossover study in which 101 subjects with type II diabetes completed the SF-36v2 
on two modalities: paper and either the electronic handheld (PHT LogPad® LW) 
or the smartphone App (PHT LogPad App). Subjects completed the assessment in 
a single session with distraction activities between completion of the first and 
second modality and an exit survey which assessed patient preference for mode of 
administration. Results: Study data will be analyzed to test score level equivalence 
and to calculate the intraclass correlation coefficient (ICC) and other measures of 
measurement equivalence. Equivalence analysis is in progress, and findings will 
be ready to present for this meeting. 82% of subjects found the electronic method 
easy to use and 80% found it easy to navigate. Of those subjects who expressed a 
preference, 57% found it more physically comfortable and 69% found it faster to 
complete than paper. 65% would prefer the electronic method over paper when 
responding to questions in a clinical trial. cOnclusiOns: This study will evaluate 
the measurement equivalence between standard paper versions of the SF-36v2 
and electronic handheld versions as deployed on an electronic handheld device or 
a smartphone App. Patients with diabetes generally prefer to complete the SF-36v2 
electronically rather than on paper.
PRM106
develoPMent and validation of the angiotensin-conveRting enzyMe 
inhibitoR (acei) induced angioedeMa investigatoR Rating scale and 
PRoPosed dischaRge cRiteRia
Bonner N.1, Kimura A.2, Panter C.1, Sinert R.3, Moellman J.J.4, Bernstein J.A.4
1Adelphi Values Ltd, Bollington, UK, 2Shire HGT, Lexington, MA, USA, 3SUNY - Downstate Medical 
Centre, Brooklyn, NY, USA, 4University of Cincinnati, Cincinnati, OH, USA
Objectives: Angiotensin-converting enzyme inhibitors (ACEI) have been impli-
cated in bradykinin-mediated angioedema. With ever-widening indications for 
ACEI including hypertension, congestive heart failure, diabetic nephropathy, 
etc., a concomitant increase in ACEI-Angioedema (ACEI-A) has been reported. 
At present there is no validated severity scoring or discharge criteria for ACEI-A. 
We sought to develop an investigator rating scale with corresponding discharge 
criteria. This study aimed to confirm the clinical relevance, content validity, and 
reliability of the scale with clinicians experienced in treating ACEI-A. MethOds: 
In-depth, 60-minute qualitative telephone interviews were conducted with 12 
US-based emergency physicians. Beforehand, clinicians were sent four case stud-
ies describing patients experiencing different severities of angioedema attacks. 
Clinicians were initially asked open-ended questions about their experience of 
patients’ symptoms, treatment and discharge decisions. Clinicians then rated 
each patient case study and discussed patient diagnoses, ratings of symptom 
severity and discharge evaluation. The ratings were used to assess inter-rater 
reliability of the scale using the intra-class correlation coefficient (ICC) using IBM 
SPSS analysis Version 19 software. Results: The findings provide support for 
focus on the four key symptoms of airway compromise scored on a 0-4 scale: 
1) Difficulty Breathing, 2) Difficulty Swallowing, 3) Voice Changes and 4) Tongue 
Swelling and the corresponding discharge criteria of a score of 0 or ‘No symptoms’ 
for Difficulty Breathing and Difficulty Swallowing and a score of 0 or 1 indicat-
ing mild or absence of symptoms for Voice Change and Tongue Swelling. Eleven 
clinicians agreed the absence of standardized discharge criteria supported the 
use of the scale and all physicians concurred with the recommended discharge 
criteria. The clinician ratings provided evidence of strong inter-rater reliability 
for the rating scale (ICC> 0.80). cOnclusiOns: The investigator rating scale and 
discharge criteria are clinically valid, relevant and reliable. Moreover, both address 
the current unmet need for standardized discharge criteria.
PRM107
develoPMent of a disease Model foR sPoRadic inclusion body 
Myositis (sibM)
Gnanasakthy A.1, DeMuro C.1, Lewis S.1, Tseng B.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals, Cambridge, 
MA, USA
Objectives: sIBM is a progressive idiopathic inflammatory myopathy characterized 
by the asymmetric atrophy and weakness of proximal and distal muscle groups. 
Atrophy of the quadriceps, wrist, and finger flexor muscles and dysphagic pro-
cesses are clinical hallmarks and result in significant functional disabilities with 
progression. To understand impact on patients, a qualitative study was conducted to 
support the development of a disease model depicting relationships among patient 
concepts relevant to disease progression that may be impacted by the treatment of 
sIBM. No such disease model is currently available. MethOds: A literature review 
was conducted to determine a preliminary understanding of the impact of sIBM. 
This was followed by therapeutic area expert input and interviews of patients diag-
nosed with sIBM (n = 20). Based on all results, a model was constructed. Results: 
Results from literature and expert input allowed for the development of an initial 
diagram depicting a proposed pathway from a diagnosis of sIBM, modifying factors 
(e.g. age, gender, duration, severity, falls), proximal concepts of signs and symptoms 
of disease (weakness, atrophy), functioning (upper extremity, lower extremity, gen-
eral, swallowing) and through more distal psychosocial concepts (emotions, mood, 
relationships). Patient feedback was used to further refine the model. Some physical 
1) to fill in the questionnaire online, focusing on the instructions developed for 
online use; 2) to comment on their understanding of the instructions and suggest 
alternative formulations in case of problematic wording; and 3) to comment on 
the online administration and handiness of the version on the device (i.e., leg-
ibility of the instructions and items/response choices). After the test session, the 
interviewer asked questions about easiness of completion, navigation, instruc-
tions, screen and font size, and also reported on any hesitations or questions 
asked by the patient during the process. The severity of the issues encountered 
during the test was divided into three levels with level 1 indicating inability of 
use and/or incomprehensibility of instructions. Results: All respondents were 
able to answer the questions on their own without help. The respondents found 
the instructions very clear, and completing the online versions of the instruments 
proved to be easy and quick. For those who wished to correct their answers, going 
back to the previous screens was also easy. Minor changes were suggested to the 
screen resolution, font size of the response choices of the AQLQ(S)+12, and to 
the background colour. It was also suggested the number of questions should be 
included on the first screen. The online versions were revised accordingly. All par-
ties involved agreed that there was no need for further testing. cOnclusiOns: 
The web-based UK versions of the AQLQ(S)+12 and (ACQ-6) proved to be easy to 
use and understandable with minor improvements.
PRM103
develoPMent and content validity of a PediatRic functional 
constiPation daily diaRy
Turner-Bowker D.M.1, Lindner E.2, Mareya S.2, Losch-Beridon T.2, Elash C.A.1, Paty J.3,  
Keithly S.4, Ascoytia C.4
1ERT, Pittsburgh, PA, USA, 2Sucampo Pharma Americas LLC, Bethesda, MD, USA, 3Quintiles, 
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Objectives: To demonstrate how patient and parent/legal guardian interviews 
reinforce a conceptual model of pediatric functional constipation signs, symp-
toms, and impact for inclusion in a Pediatric Functional Constipation Daily Diary 
(PFC-DD); and to evaluate patient and parent/legal guardian comprehension and 
usability of the PFC-DD administered via electronic diary. MethOds: Qualitative 
patient interviews were conducted with pediatric patients who have functional 
constipation and their parent/legal guardian to determine the most important 
and relevant signs, symptoms, and impacts associated with the condition, and 
to evaluate comprehension and usability of the draft PFC-DD. Concept elicitation 
(CE) and cognitive interviews (CI) were conducted with the parent/legal guardian 
of children ages 6 months to < 6 years (CE, n= 18; CI, n= 11), and with children/
adolescents ages 6 to < 18 years and their parent/legal guardian (CE, n= 18; CI 
patient n= 21, parent n= 20). Results: For both groups, the predominant sign/
symptom concepts reported were: stool consistency changes, toileting avoidance 
and/or retentive posturing, child report and/or behaviors suggesting abdominal 
pain, difficulty while toileting (e.g., straining, rectal pain), infrequent bowel move-
ments, and appetite changes. Parents of children ages 6 months to < 6 years also 
reported abdominal hardness, gas, and soiling. The predominant impacts reported 
were limitations in physical activity, emotional and social function, sleep (younger 
age group only), school participation (older age group only), and coping strategies 
(e.g., medications/supplements). Results from the CIs indicated no comprehension 
problems for most items. However, minor revisions (e.g., definition for ‘reten-
tive posturing’) were made to the wording of a few items to improve clarity and 
appropriate understanding of the concept. No concerns were raised about the 
usability of the electronic diary. cOnclusiOns: Findings support the content 
validity of the PFC-DD, a new instrument that includes PRO and ObsRO items to 
assess the key signs, symptoms, and impacts experienced by pediatric patients 
with functional constipation.
PRM104
When the liteRal Meaning Just Won’t do - cultuRal adaPtation 
issues Resolved duRing the linguistic validation of a behaviouRal 
scale
Williams H., Oke L., Scharf L., Anderson H., Gergovich B.
ICON Plc, Oxford, UK
Objectives: (1) To identify the translation issues during linguistic validation of 
a behavioural scale, (2) to ascertain whether the same issues appeared in more 
than one language, (3) to determine what solutions were found to ensure con-
ceptual accuracy, with a view to collecting consistently valid data across the 
study. MethOds: 28 back translation and psychologist reviews of a behavioural 
scale were examined, in which translation issues had been discussed at length 
between lead translators, project managers and experts in the field. Information 
was gathered on the translation difficulties that arose in each language and the 
results were compared in order to identify patterns. Results: Three main cat-
egories of discussion were identified: Transferral of word length and complexity 
was particularly important. Literal translations needed replacing with culturally 
adapted wording across a high percentage of the languages to ensure overall 
conceptual equivalence. Many idioms and common phrases were found to be non-
sensical when translated literally. Across all languages, expressions like ‘Button 
your lip’ and ‘Hit the road’ were replaced with localised sayings that would enable 
conceptual comprehension of the items. Questions regarding grammar and tense 
led to alterations and omissions in a number of languages due to dramatic dif-
ferences in language structure across the world. In questions regarding irregular 
verb use, for example, most languages replaced the examples or removed them 
altogether if no such irregular verbs existed. cOnclusiOns: The behavioural 
scale was found to contain many translation issues arising from its focus on 
language specific distinctions. Patterns were found in the resolution of these 
issues and changes often necessitated moving away from a literal translation 
so that concepts and ideas could be appropriately conveyed. This highlights the 
importance of linguistic validation and its ability to improve translation quality 
for cross-cultural comparison.
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Quality (AHRQ) comparative effectiveness report on treatments for seasonal aller-
gic rhinitis, which used a non-anchor based approach. Results: Using the most 
conservative estimates provided within the approved prescribing information, the 
change in rTNSS from baseline was -1.18 (p = 0.02) for azelastine hydrochloride, 
-1.35 (p = 0.014) for ciclesonide, -1.47 (p < 0.001) for fluticasone furoate, and -2.7* 
for MP29-02†(p < 0.001). Direct anchor-based estimates of MCID derived by Barnes 
and colleagues ranged from 0.28 units (95% CI: -0.18 to 0.73) and 0.23 units (95% 
CI: -0.16 to 0.62). Comparison of the anchor-based MCID threshold to the observed 
treatment indicates a positive clinical benefit for each treatment option. In con-
trast, the AHRQ report concluded that treatment options were equivalent to each 
other, to intranasal corticosteroids and to placebo, in contrast to common patient 
beliefs. cOnclusiOns: Anchor based methods are critical in evaluating MCID as 
demonstrated by comparison of outcomes across intranasal products for seasonal 
allergic rhinitis. MCID methods need to be considered when evaluating evidence 
for health technology assessments. * Range of rTNSS is 0-12; 0-24 for MP29-02 † 
Dymista® = US trade name of MP29-02
PRM111
can’t We Just use this PoRtuguese tRanslation in bRazil? analysing 
Why theRe is MoRe to countRy-sPecific PRos than ticking/checking 
boxes
Simpson H., Bellhouse G., Neal R., Two R.
PharmaQuest Ltd., Bloxham, UK
Objectives: It is well established that translations of patient-reported outcome 
(PRO) measures need to be linguistically validated for the country or countries they 
will be used in - whether that means adapting an existing language version for 
use in a new country, or developing a language version for multiple countries from 
the beginning. While it is generally agreed that adaptations must be validated for 
their target countries, we aim to illustrate to stakeholders that there is more to 
this process than just a box-ticking exercise, by exploring the country-specific dif-
ferences that affect translations of PRO measures, and the implications they may 
have for the resulting patient data. MethOds: We analysed examples from nearly 
ten years of in-house projects involving the adaptation of existing language ver-
sions for new target countries. A range of wording changes within these adaptation 
projects were identified and categorised according to their nature (linguistic varia-
tions or culturally-bound terms) and their position in the PRO (instruction, item or 
response option). We then further assessed the significance of each change and the 
possible impact on the respondent’s understanding of the measure and their ability 
to answer the items meaningfully. Results: The results of the two-part analysis 
illustrate that although many differences between country-specific language ver-
sions may be considered inconsequential (i.e. if a UK spelling of an English word 
is used in the US, it may still be understood), depending on the type of linguistic 
variation and its prominence within the PRO itself, in some cases there is a real 
risk that without the change an item may be misinterpreted or even impossible to 
answer. cOnclusiOns: The evidence provided by the linguistic and culturally-
bound changes made during in-country adaptation projects emphasises why the 
process of adapting a measure to its target country is invaluable for its successful 
administration.
PRM112
validation of a vitality quotient to MeasuRe the effect of food 
suPPleMents on fatigue in healthy subJects
Allaert F.1, Courau S.2, Forestier A.2
1Medical evaluation Chair ESC Dijon, Dijon, France, 2Merck CH, Dijon, France
Objectives: validation of the psychometric properties of the “vitality quotient” 
questionnaire (VQ) i.e. the measures of its internal consistency, external validation 
and sensitivity to change. MethOds: Prospective observational survey on patients 
consulting for fatigue and taking Bion3® during winter . The VQ includes 10 ques-
tions describing subjects’ activities and mood, rated from “1: very often” to “10: 
never”. Its comprehensibility and test-retest reliability has been evaluated in one 
other study. Each patient fulfil the VQ and the Pichot scale which is a reference scale 
for fatigue evaluation at inclusion and every month during three months. Internal 
consistency of the QV was measured with Cronbach’s alpha coefficient, external 
validation by its correlation coefficient with Pichot scale and its sensitivity to change 
by the paired T test of its average variations during the study period. Results: 132 
subjects 48.2 ± 13.5 years old (63.6% women) were followed. The Cronbach’s alpha 
coefficient has a very high level of 0.93 and therefore indicates a very good internal 
consistency. The study of the VQ correlation with the fatigue scale of Pichot at 
baseline shows a high Pearson coefficient of r = -0.67 (p < 0.0001) and the study of 
the correlation of their changes during the three months is of r = -0.75 (p < 0.0001). 
The QV is also sensitive to change. After one month the VQ increases from 47.3 ± 
18.5 to 60.4 ± 20.5 and then to 73.5 ± 18.0 after 2 months and to 80.9 ± 18.1 after 3 
months which is highly significant (p< 0,0001) and corresponds to improvements of 
respectively +27.7%, +55.4% and +71.0% of the initial vitality of the subjects taking 
Bion3®. cOnclusiOns: This study validates psychometrics properties (reliability, 
external validity and sensitivity to change) of the « vitality quotient » which appears 
an effective to evaluate food supplements effects in healthy subjects complaining 
of fatigue and expressing a loss of vitality.
PRM113
challenges faced duRing linguistic validation foR south afRica
Towns L., Williams H., Anderson H., Gergovich B.
ICON Plc, Oxford, UK
Objectives: (1) To investigate the difficulties experienced during translation of 
Clinical Outcomes Assessments for South Africa with regard to the existence of mul-
tiple official languages (2) To identify patterns of terminology usage across different 
settings in South Africa MethOds: Back translation and cognitive debriefing reviews 
were reviewed across multiple South African languages from linguistic validation 
projects. The results were compared and challenges with conceptual equivalence 
impacts were described as difficulty standing from a seated position or using stairs 
in early disease followed by increased falls, gait impairment, and progressive loss of 
ambulation resulting in the need for assistive devices. Upper extremity weakness 
results in difficulty with activities requiring gripping and lifting. Dysphagia can 
include swallowing difficulties, choking, and interference with nutritional intake. 
Psychosocial impacts were often related to the loss of autonomy, fear of falls, social 
and familial impacts and the need for assistance. cOnclusiOns: This sIBM disease 
model adds significantly to the literature describing the patient impact of sIBM and 
may be used to guide selection of clinical trial endpoints.
PRM108
health-Related quality of life aMong esRf Patients in Pakistan: a 
cRoss-sectional aPPRoach using Whoqol-bRef
Iqbal M.Z.1, Iqbal M.S.2, Iqbal M.W.3, Bahari M.B.2, Nasir S.4
1Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 
Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of 
Pharmacy, AIMST University, Kedah, Malaysia, 2Department of Clinical Pharmacy & Pharmacy 
Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 3Faculty of Law, University of 
Malaya, Kualalumpur, Malaysia, 4Nishtar Hospital, Multan, Pakistan
Objectives: To evaluate health-related quality of life (HRQoL) of End Stage Renal 
Failure (ESRF) patients in Pakistan. MethOds: A prospective cross-sectional study 
was conducted at a tertiary care hospital in a province of Pakistan, the Punjab. 
WHOQOL-BREF (Urdu version, pretested for reliability and validity) was used as 
research instrument. Data was obtained through face-to-face interviews and where 
possible by gender-based focus group sessions. WHOQOL-BREF score was obtained 
and evaluated to determine HRQoL of ESRF patients. Patients were also asked 
to share their personal experiences of being diagnosed and treatment given. All 
obtained data were analyzed using descriptive and inferential statistics by using 
SPSS 20.0. Results: The overall Cronbach’s alpha coefficient of the revalidated 
WHOQOL-BREF questionnaire was 0.799. The scores for negative feelings, depres-
sion, living place, personal relationships and sexual life were significantly different 
in the psychological health and social relations domains. Mean age, gender, educa-
tion level, occupation and physical exercise were also significantly associated with 
the HRQoL of the ESRF patients. cOnclusiOns: The WHOQOL-BREF was a reliable 
and valid research tool to evaluate HRQoL of ESRF patients in Pakistan. A significant 
impact on HRQoL of the ESRF patients was observed. Together with curative and pre-
ventative measures, there is also a great need to measure HRQoL of ESRF patients.
PRM109
challenges in tRanslating the conneRs 3Rd edition–PaRent into 12 
languages
Verne A., Bailly C., Rouillat C.
Mapi, Lyon, France
Objectives: The Conners 3rd Edition–Parent (Conners 3–P) is used to obtain par-
ents’ observations about the behaviors and feelings of children and adolescents 
aged 6-18 years old. Developed in American English and published by Multi-Health 
Systems, it was designed to assess Attention Deficit/Hyperactivity Disorder 
(ADHD). The short version provides the evaluation of inattention, hyperactivity/
impulsivity, learning problems, executive functioning, aggression, and peer rela-
tions, and includes 43 items rated on a 4-point scale (“Not true at all” to “Very 
much true”). The objective of this study is to present the challenges faced during 
the translation of the instrument into ten Indo-European languages (English for 
four countries, French, Italian, German, Spanish for three countries), one Sino-
Tibetan (Chinese), and one Austronesian language (Malay). MethOds: The fol-
lowing translation method was used: 1. Concept definition; 2. Forward/backward 
translation [or adaptation for English and Spanish versions (i.e., for Argentina 
and Mexico)]; 3. Review of the back-translations/adaptations by the copyright 
holder of the instrument; and 4. Cognitive interviews with five parents in each 
country. Results: The translation process did not reveal any cultural issues since 
most of the concepts assessed were cross-culturally relevant. The main difficul-
ties consisted in finding conceptual equivalents of the original items with strong 
idiomatic content. For instance, the most challenging items were items 13 (“Acts 
as if driven by a motor”), 31 (“Tells the truth; doesn’t even tell “little white lies.”), 
and 40 (“Behaves like an angel”). Most of the solutions were found using concept 
definitions. Parents were important in discussing changes or proposing solu-
tions. Examples will be provided. cOnclusiOns: The multi-step process proved 
to be critical to ensure the production of conceptually equivalent and culturally 
appropriate translations of the Conners 3–P into Indo-European, Sino-Tibetan and 
Austronesian languages. The involvement of the copyright holder and of parents 
was crucial in finding solutions.
PRM110
the iMPoRtance of anchoR based MiniMal clinically iMPoRtant 
diffeRence (Mcid) to health technology assessMent of established 
intRanasal alleRgic Rhinitis tReatMents
Brixner D.1, Meltzer E.O.2, Morland K.3, Carroll C.A.3, Lipworth B.J.4
1University of Utah, Salt Lake City, UT, USA, 2Allergy and Asthma Medical Group and Research 
Center, San Diego, CA, USA, 3Xcenda, Palm Harbor, FL, USA, 4Ninewells Hospital and School of 
Medicine, Dundee, UK
Objectives: Anchor based methods are commonly used to derive MCID in treat-
ment assessments. The objective of this work was to compare the outcomes of 
an anchor-based vs. non-anchor based methodology in the health technology 
assessment of intranasal allergic rhinitis treatments. MethOds: Data specific to 
the treatment benefit (active drug versus vehicle placebo) of 4 intranasal seasonal 
allergic rhinitis treatments (azelastine hydrochloride, ciclesonide, fluticasone furo-
ate, MP29-02) using the reflective Total Nasal Symptom Score (rTNSS) were obtained 
from the FDA approved prescribing information. Anchor-based MCID estimates 
reported from Barnes et al. 2010 were then compared to the treatment effect. The 
outcomes were then compared to the July 2013 Agency for Healthcare Research & 
